Jazz Jumps On Defibrotide Priority Review

Shares of Jazz Pharmaceuticals plc jumped 8% in morning trading on Sept. 30 on word the FDA had granted a priority review of the company's new drug application (NDA) for its anticoagulant defibrotide as a treatment for patients with hepatic veno-occlusive disease (VOD) with evidence of multi-organ dysfunction (MOD) following hematopoietic stem-cell transplantation (HSCT).

The FDA has set March 31, 2016 as the Prescription Drug User Fee Act action date for the defibrotide NDA...